Psoriasis (PsO) is a systemic autoimmune disease. Many pro‐inflammatory and anti‐inflammatory biomarkers have been associated with the pathogenetic process of psoriasis. IL‐35 act as an anti‐inflammatory cytokine through downregulation of… Click to show full abstract
Psoriasis (PsO) is a systemic autoimmune disease. Many pro‐inflammatory and anti‐inflammatory biomarkers have been associated with the pathogenetic process of psoriasis. IL‐35 act as an anti‐inflammatory cytokine through downregulation of TH‐17 cell development and cytokine production. So, IL‐35 might be utilized as potential future therapeutic agent for psoriasis.
               
Click one of the above tabs to view related content.